Cytotoxic NK Cells Impede Response to Checkpoint Immunotherapy in Melanoma with an Immune-Excluded Phenotype
Joanna Poźniak(VIB-KU Leuven Center for Cancer Biology), Jean‐Christophe Marine(VIB-KU Leuven Center for Cancer Biology), Zihai Li(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Oliver Bechter(Universitair Ziekenhuis Leuven), No‐Joon Song(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Francesca M. Bosisio(Universitair Ziekenhuis Leuven), Lukas Vanwynsberghe(VIB-KU Leuven Center for Cancer Biology), Yannick Van Herck(Universitair Ziekenhuis Leuven), Philip Georg Demaerel(Universitair Ziekenhuis Leuven), Christos Gkemisis(VIB-KU Leuven Center for Cancer Biology), Robin Browaeys(Ghent University), Niccolò Roda(VIB-KU Leuven Center for Cancer Biology), Veerle Boecxstaens(Universitair Ziekenhuis Leuven), Ewout Landeloos(VIB-KU Leuven Center for Cancer Biology), Jeroen Declercq(KU Leuven), Patrick Matthys(KU Leuven), Diether Lambrechts(VIB-KU Leuven Center for Cancer Biology), Amber De Visscher(Rega Institute for Medical Research), Greet Bervoets(VIB-KU Leuven Center for Cancer Biology), Ayse Bassez(Vlaams Instituut voor Biotechnologie), Yvan Saeys(HOGENT University of Applied Sciences and Arts), Lotte Pollaris(VIB-UGent Center for Inflammation Research), Asier Antoranz(KU Leuven)
Cited by 20
Related Papers
A comparison of single-cell trajectory inference methods
|Nature Biotechnology|2019|1.7k
Melanoma addiction to the long non-coding RNA SAMMSON
|Nature|2016|588
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
|The Lancet|2017|580
MDM4 is a key therapeutic target in cutaneous melanoma
|Nature Medicine|2012|305